---
title: "AbbVie Updates Phase 2 Elezanumab Study in Acute Cervical Spinal Cord Injury"
pubDate: 2026-02-15
brief: "This clinical study update examines the safety and efficacy of elezanumab in improving arm and hand movement following serious neck-level spinal cord injuries. The drug is designed to block molecules that inhibit nerve regrowth, aiming to restore physical function in patients during the acute phase of injury."
techRating: 3
category: ["Pharmacology", "Clinical Trial"]
sourceUrl: "https://www.theglobeandmail.com/investing/markets/stocks/ABBV-N/pressreleases/187072/abbvie-updates-phase-2-elezanumab-study-in-acute-cervical-spinal-cord-injury-what-investors-should-watch/"
---
